Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer

NCT00022698 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00022698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2001
Completion date
December 31, 2004
Enrollment
67 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer